Keyphrases
Chronic Lymphocytic Leukemia
68%
T Cells
64%
CD4 Cells
57%
Leukemia
45%
Genetic Modification
41%
Therapeutic Target
34%
Nuclear factor-B
33%
Toleration
31%
Self-antigens
29%
In Cancer
27%
CD8+ T Cells
26%
Cancer Treatment
26%
Antibody-drug Conjugate
26%
Histone Acetylation
24%
Ibrutinib
24%
Acute Myeloid Leukemia
23%
Interleukin-2
22%
Acute Lymphoblastic Leukemia
22%
Immune Suppression
22%
Genetic Ancestry
22%
T Cell Bispecific Antibodies
22%
PDK1
20%
Gene Expression
19%
Targeted Therapy
19%
Costimulation
18%
Regulatory T (Treg) Cells
18%
Pan-cancer
16%
Cancer Genome
16%
T Cell Response
16%
NF-B
16%
T Cell Activation
16%
Mantle Cell Lymphoma
15%
Effector Memory T Cells
15%
Leukemia Patients
15%
Transcription Factor
15%
Evolutionary Genomics
15%
CD137
15%
Druggable Gene
15%
Cancer Types
14%
CD4+
14%
Effector Cytokines
14%
Programmed Death-ligand 1 (PD-L1)
14%
Chimeric Antigen Receptor T Cells (CAR-T)
13%
Thymocytes
13%
Prostate
12%
Phosphoinositide 3-kinase (PI3K)
12%
Activation-induced Cell Death
12%
Cell Function
12%
Prostate Cancer
12%
Tumor Immunity
12%
Immunology and Microbiology
T Cell
100%
CD4
67%
Cytotoxic T-Cell
39%
Interleukin 2
36%
Complement Factor B
33%
Regulatory T Cell
30%
Cytokine
30%
T Cell Receptor
29%
T-Helper Cell
24%
B Cell
24%
Mouse Model
23%
Tumor Necrosis Factor
23%
Bispecific Antibody
22%
Transcription Factors
22%
CD8
22%
CD3 Antigen
16%
Leukemia Cell
16%
Promoter Region
15%
Cell Death
13%
Chimeric Antigen Receptor T-Cell
13%
Histone Acetylation
13%
Thymocyte
13%
T Cell Development
12%
B-Cell Receptor
12%
Myeloid
12%
Cell Migration
12%
Engraftment
11%
CD33
11%
Humanized Mouse
11%
Gene Expression
11%
Adoptive Immunotherapy
11%
Inflammation Response
11%
CD134
11%
Prostate
11%
P110δ
11%
Homeostasis
11%
Transcriptomics
11%
Caspase
11%
Interleukin 2 Receptor
11%
Cyclophosphamide
11%
Cell Adhesion
11%
Sialic Acid Binding Immunoglobulin Like Lectin
11%
Tumor Necrosis Factor Alpha
11%
Bruton Tyrosine Kinase
9%
Syngenic
8%
Mitogen
8%
Immune Evasion
8%
Cell Function
8%
Immunotherapy
7%
Immune Response
6%
Medicine and Dentistry
T Cell
73%
B-Cell Chronic Lymphocytic Leukemia
45%
Leukemia
33%
Ibrutinib
24%
Antibody-Drug Conjugate
22%
T-Helper Cell
21%
Acute Lymphoblastic Leukemia
18%
Mantle Cell Lymphoma
15%
T-Cell Response
15%
Immunotherapy
14%
Malignant Neoplasm
13%
Cell Migration
13%
Regulatory T Cell
12%
Receptor
12%
Interleukin 2
12%
Phosphoinositide 3-Kinase
11%
Engraftment
11%
Homeostasis
11%
Cancer Therapy
11%
Small Cell Lung Cancer
11%
Bispecific Antibody
11%
Programmed Death 1 Ligand 1
11%
Histone Acetylation
11%
Androgen
11%
Radioimmunotherapy
11%
Chimeric Antigen Receptor T-Cell
11%
Antivirus Agent
11%
Immunosuppressive Treatment
11%
Prostate Cancer
11%
Sialic Acid Binding Immunoglobulin Like Lectin
11%
Cell Adhesion
11%
Phosphoinositide Dependent Protein Kinase 1
9%
T Lymphocyte Receptor
9%
Cytotoxic T-Cell
9%
Leukemia Cell
9%
Cancer
8%
Clinical Trial
7%
Chimeric Antigen Receptor T-Cell Immunotherapy
7%
Mantle Cell Lymphoma Cell
6%
Colitis
6%
Cell Function
5%
Combination Therapy
5%
Clinical Study
5%
